[{"address1": "910 Clopper Road", "address2": "Suite 201S", "city": "Gaithersburg", "state": "MD", "zip": "20878", "country": "United States", "phone": "240 654 1450", "website": "https://altimmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Dr. Vipin K. Garg Ph.D.", "age": 65, "title": "President, CEO & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 986142, "exercisedValue": 0, "unexercisedValue": 4219457}, {"maxAge": 1, "name": "Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS", "age": 70, "title": "Chief Medical Officer", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 681809, "exercisedValue": 0, "unexercisedValue": 1413049}, {"maxAge": 1, "name": "Mr. Raymond M. Jordt M.B.A.", "age": 50, "title": "Chief Business Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 578850, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard I. Eisenstadt M.B.A.", "age": 65, "title": "Chief Financial Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 619694, "exercisedValue": 0, "unexercisedValue": 273375}, {"maxAge": 1, "name": "Mr. Bertrand  Georges Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. M. Scot Roberts Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 599255, "exercisedValue": 0, "unexercisedValue": 565469}, {"maxAge": 1, "name": "Mr. Tony  Blandin B.S.", "title": "Vice President of Quality & Compliance Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Shutterly M.S.", "title": "Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 4, "overallRisk": 8, "governanceEpochDate": 1711670400, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome", "maxAge": 86400, "priceHint": 2, "previousClose": 10.18, "open": 10.27, "dayLow": 9.89, "dayHigh": 11.01, "regularMarketPreviousClose": 10.18, "regularMarketOpen": 10.27, "regularMarketDayLow": 9.89, "regularMarketDayHigh": 11.01, "exDividendDate": 1484870400, "beta": 0.069, "forwardPE": -6.3937497, "volume": 5073903, "regularMarketVolume": 5073903, "averageVolume": 6008374, "averageVolume10days": 4436806, "averageDailyVolume10Day": 4436806, "marketCap": 725258816, "fiftyTwoWeekLow": 2.09, "fiftyTwoWeekHigh": 14.84, "priceToSalesTrailing12Months": 1702.4855, "fiftyDayAverage": 9.9271, "twoHundredDayAverage": 5.74445, "currency": "USD", "enterpriseValue": 528114784, "floatShares": 70334504, "sharesOutstanding": 70895296, "sharesShort": 12511448, "sharesShortPriorMonth": 11552689, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.177, "heldPercentInsiders": 0.0077600004, "heldPercentInstitutions": 0.51634, "shortRatio": 2.01, "shortPercentOfFloat": 0.17809999, "impliedSharesOutstanding": 70895296, "bookValue": 2.746, "priceToBook": 3.7254186, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -88447000, "trailingEps": -1.66, "forwardEps": -1.6, "lastSplitFactor": "1:30", "lastSplitDate": 1536883200, "enterpriseToRevenue": 1239.706, "enterpriseToEbitda": -6.36, "52WeekChange": 1.487864, "SandP52WeekChange": 0.28136122, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ALT", "underlyingSymbol": "ALT", "shortName": "Altimmune, Inc.", "longName": "Altimmune, Inc.", "firstTradeDateEpochUtc": 1495805400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "dfbfc9cc-7a23-3560-b04c-b1a5faf1ec3e", "messageBoardId": "finmb_4866807", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.23, "targetHighPrice": 35.0, "targetLowPrice": 13.0, "targetMeanPrice": 21.75, "targetMedianPrice": 22.5, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 197815008, "totalCashPerShare": 2.79, "ebitda": -83033000, "totalDebt": 671000, "quickRatio": 16.69, "currentRatio": 17.263, "totalRevenue": 426000, "debtToEquity": 0.346, "revenuePerShare": 0.008, "returnOnAssets": -0.24999, "returnOnEquity": -0.46626, "freeCashflow": -49978624, "operatingCashflow": -75810000, "operatingMargins": -573.0811, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-02"}]